search
Back to results

Optimal Vitamin D3 Supplementation Strategies for Acute Fracture Healing (Vita-Shock)

Primary Purpose

Fracture

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Vitamin D3
Placebo
Sponsored by
University of Maryland, Baltimore
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Fracture focused on measuring Tibial Shaft, Tibia, Femoral Shaft, Femur, Vitamin D, Fracture Healing

Eligibility Criteria

18 Years - 50 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Adult men or women ages 18-50 years
  2. Closed or low grade open (Gustilo type I or II) tibial or femoral shaft fracture
  3. Fracture treated with a reamed, locked, intramedullary nail
  4. Acute fracture (enrolled within 7 days of injury)
  5. Provision of informed consent.

Exclusion Criteria:

  1. Osteoporosis
  2. Stress fractures
  3. Elevated serum calcium (>10.5 mg/dL)
  4. Atypical femur fractures as defined by American Society for Bone and Mineral Research (ASBMR) criteria
  5. Pathological fractures secondary to neoplasm or other bone lesion
  6. Patients with known or likely undiagnosed disorders of bone metabolism such as Paget's disease, osteomalacia, osteopetrosis, osteogenesis imperfecta etc.
  7. Patients with hyperhomocysteinemia
  8. Patients with an allergy to vitamin D or another contraindication to being prescribed vitamin D
  9. Patients currently taking an over the counter multivitamin that contains vitamin D and are unable or unwilling to discontinue its use for this study
  10. Patients who will likely have problems, in the judgment of the investigators, with maintaining follow-up
  11. Pregnancy
  12. Patients who are incarcerated
  13. Patients who are not expected to survive their injuries
  14. Other lower extremity injuries that prevent bilateral full weight-bearing by 6 weeks post-fracture.

Sites / Locations

  • University of Maryland, R Adams Cowley Shock Trauma Center
  • McMaster University, Center for Evidence-Based Orthopaedics

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Placebo Comparator

Arm Label

High Loading Dose

High Daily Dose

Low Daily Dose

Control Group

Arm Description

150,000 IU loading dose vitamin D3 at enrolment and 6 weeks, plus daily dose placebo for 3 months.

Loading dose placebo at enrolment and 6 weeks, plus 4,000 IU vitamin D3 per day for 3 months.

Loading dose placebo at enrolment and 6 weeks, plus 600 IU vitamin D3 per day for 3 months.

Loading dose placebo at enrolment and 6 weeks, plus daily dose placebo for 3 months.

Outcomes

Primary Outcome Measures

Fracture Healing Will be Assessed Clinically Using Function IndeX for Trauma (FIX-IT)
FIX-IT is a standardized measure of weight-bearing and pain in patients with lower extremity fractures, specifically tibia and femur fractures. The FIX-IT score ranges from 0 to 12 points in 2 domains: the ability to bear weight (maximum 6 points) and pain at the fracture site (maximum 6 points) The ability to bear weight is assessed through the single-leg stand and ambulation procedures. Pain is assessed through palpation and stress procedures. The scores in both domains, which are weighted equally, are summed to obtain the final total score; the maximum score of 12 indicates the highest level of function.
Fracture Healing Will be Assessed Radiographically Using Radiographic Union Score for Tibial Fractures (RUST)
Radiographic fracture healing was measured using the Radiographic Union Score for Tibial fractures (RUST), which assesses the presence of bridging callus or a persistent fracture line on each of four cortices. This method evaluates two orthogonal radiographic views; each cortex is attributed points ranging from 1 to 3. A fracture in the immediate postoperative period will receive the minimum score, 4, (1 point for each of the four cortices) and a fully consolidated or healed fracture will be assigned the maximum score, 12 (3 points on each of the four cortices).
Fracture Healing Will be Assessed Biochemically Using Serum Levels of the Bone Turnover Marker (BTM) C-terminal Telopeptide of Type I Collagen (CTX)
The BTM C-terminal telopeptide of type I collagen (CTX). CTX is a marker of bone resorption. Clinically important changes in the CTX markers are unknown; however, in a previous study of tibia fracture healing, Veitch et al observed concentrations of both bone turnover markers approximately 100% greater than baseline values.43 Given the large changes observed in these bone turnover markers, the same criteria will be applied for identifying a potentially clinically beneficial regimen and remain powered to detect a mean difference of 20% (SD 30%).
Fracture Healing Will be Assessed Biochemically Using Serum Levels of the Bone Turnover Marker N-terminal Propeptide of Type I Procollagen (P1NP)
P1NP is a bone-formation marker and prior research has found that it is highest at 12 weeks after fractures of the tibial shaft and proximal femur.

Secondary Outcome Measures

Serum Level of 25(OH)D
Correlations will be assessed between participants' 25(OH)D levels at enrolment, changes in 25(OH)D levels from enrolment to 3 months, and 25(OH)D levels at 3 months and fracture healing
Number of Participants With Adherence With Vitamin D Supplementation
Will measure adherence with vitamin D supplementation based on participants self report at the 6 week and 3 month visits.
Number of Participants With Adverse Events (AE)
A count of the participants who experienced adverse events will measure participant safety
Serum Levels of Calcium
Will measure participant safety
Serum Levels of Parathyroid Hormone
Helps the body to maintain stable levels of calcium in the blood
Count of Participants Who Completed Blood Measures
Will measure participants adherence to the blood measures of the protocol.
Count of Participants Who Completed Radiographic Imaging Measures
Count of participants who completed radiographic imaging measures to determine participant protocol adherence and assists with identifying healing status

Full Information

First Posted
May 11, 2016
Last Updated
March 21, 2022
Sponsor
University of Maryland, Baltimore
Collaborators
McMaster University
search

1. Study Identification

Unique Protocol Identification Number
NCT02786498
Brief Title
Optimal Vitamin D3 Supplementation Strategies for Acute Fracture Healing
Acronym
Vita-Shock
Official Title
A Blinded Exploratory Randomized Controlled Trial (RCT) to Determine Optimal Vitamin D3 Supplementation Strategies for Acute Fracture Healing
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Completed
Study Start Date
November 21, 2016 (Actual)
Primary Completion Date
August 2019 (Actual)
Study Completion Date
December 1, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Maryland, Baltimore
Collaborators
McMaster University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The objective is to determine the effect of vitamin D3 supplementation on fracture healing at 3 months.
Detailed Description
Vitamin D supplements are increasingly being recommended to healthy adult fracture patients without an osteoporotic injury. Although this is a relatively new practice pattern, the basis for this adjunct therapy is grounded in the high hypovitaminosis D prevalence rates (up to 75%) among healthy adult fracture patients, and the strong biologic rationale for the role of vitamin D in fracture healing. Briefly, experimental animal studies have demonstrated that the concentration of vitamin D metabolites is higher at a fracture callus compared to the uninjured contralateral bone, vitamin D supplementation leads to decreased time to union and increased callus vascularity, and increases mechanical bone strength compared to controls. While evidence to confirm that vitamin D supplementation improves fracture healing in clinical studies does not exist, the pre-clinical data are compelling and worthy of further investigation. With modern orthopaedic surgical care, rates of complications following tibia and femoral shaft fractures can be as high as 15%. Complications, including delayed union, nonunion, or infection often require secondary surgical procedures and result in profound personal and societal economic costs. While surgeons continue to seek advances in surgical technique, it is becoming increasingly obvious that innovations in orthopaedic techniques or implants are unlikely to eliminate complications. As a result, considerable attention is currently focused on adjunct biologic therapies, such as vitamin D. A recent survey of 397 orthopaedic surgeons showed that only 26% routinely prescribe vitamin D supplementation to adult fracture patients. Of the 93 surgeons who indicated that they routinely prescribe vitamin D supplementation, 29 different dosing regimens were described ranging from low daily doses of 400 IU to loading doses of 600,000 IU. This suggests a high level of clinical uncertainty surrounding the use and optimal dose of vitamin D supplementation in adult fracture patients. If vitamin D supplementation improves fracture healing outcomes, then there is a large opportunity to increase its use; however, before widespread adoption occurs, research is needed to optimize the dosing strategy, establish the dosing safety in the immobilized fracture healing population, and overcome potential medication adherence issues among the often marginalized patients that suffer trauma. The long-term goal of our research program is to conduct a large phase III RCT to determine which dose of vitamin D3 supplementation optimally improves acute fracture healing outcomes in healthy adult patients (18-50 years). The current proposed phase II exploratory trial will perform important preliminary work to test the central hypothesis that vitamin D3 dose and timing of administration is critical for improving fracture healing at 3 months. This trial will also inform the feasibility of the large phase III RCT.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fracture
Keywords
Tibial Shaft, Tibia, Femoral Shaft, Femur, Vitamin D, Fracture Healing

7. Study Design

Primary Purpose
Other
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
102 (Actual)

8. Arms, Groups, and Interventions

Arm Title
High Loading Dose
Arm Type
Experimental
Arm Description
150,000 IU loading dose vitamin D3 at enrolment and 6 weeks, plus daily dose placebo for 3 months.
Arm Title
High Daily Dose
Arm Type
Experimental
Arm Description
Loading dose placebo at enrolment and 6 weeks, plus 4,000 IU vitamin D3 per day for 3 months.
Arm Title
Low Daily Dose
Arm Type
Experimental
Arm Description
Loading dose placebo at enrolment and 6 weeks, plus 600 IU vitamin D3 per day for 3 months.
Arm Title
Control Group
Arm Type
Placebo Comparator
Arm Description
Loading dose placebo at enrolment and 6 weeks, plus daily dose placebo for 3 months.
Intervention Type
Drug
Intervention Name(s)
Vitamin D3
Intervention Type
Other
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Fracture Healing Will be Assessed Clinically Using Function IndeX for Trauma (FIX-IT)
Description
FIX-IT is a standardized measure of weight-bearing and pain in patients with lower extremity fractures, specifically tibia and femur fractures. The FIX-IT score ranges from 0 to 12 points in 2 domains: the ability to bear weight (maximum 6 points) and pain at the fracture site (maximum 6 points) The ability to bear weight is assessed through the single-leg stand and ambulation procedures. Pain is assessed through palpation and stress procedures. The scores in both domains, which are weighted equally, are summed to obtain the final total score; the maximum score of 12 indicates the highest level of function.
Time Frame
3 months post-injury
Title
Fracture Healing Will be Assessed Radiographically Using Radiographic Union Score for Tibial Fractures (RUST)
Description
Radiographic fracture healing was measured using the Radiographic Union Score for Tibial fractures (RUST), which assesses the presence of bridging callus or a persistent fracture line on each of four cortices. This method evaluates two orthogonal radiographic views; each cortex is attributed points ranging from 1 to 3. A fracture in the immediate postoperative period will receive the minimum score, 4, (1 point for each of the four cortices) and a fully consolidated or healed fracture will be assigned the maximum score, 12 (3 points on each of the four cortices).
Time Frame
3 months post-injury
Title
Fracture Healing Will be Assessed Biochemically Using Serum Levels of the Bone Turnover Marker (BTM) C-terminal Telopeptide of Type I Collagen (CTX)
Description
The BTM C-terminal telopeptide of type I collagen (CTX). CTX is a marker of bone resorption. Clinically important changes in the CTX markers are unknown; however, in a previous study of tibia fracture healing, Veitch et al observed concentrations of both bone turnover markers approximately 100% greater than baseline values.43 Given the large changes observed in these bone turnover markers, the same criteria will be applied for identifying a potentially clinically beneficial regimen and remain powered to detect a mean difference of 20% (SD 30%).
Time Frame
3 months post-injury
Title
Fracture Healing Will be Assessed Biochemically Using Serum Levels of the Bone Turnover Marker N-terminal Propeptide of Type I Procollagen (P1NP)
Description
P1NP is a bone-formation marker and prior research has found that it is highest at 12 weeks after fractures of the tibial shaft and proximal femur.
Time Frame
3 months post-injury
Secondary Outcome Measure Information:
Title
Serum Level of 25(OH)D
Description
Correlations will be assessed between participants' 25(OH)D levels at enrolment, changes in 25(OH)D levels from enrolment to 3 months, and 25(OH)D levels at 3 months and fracture healing
Time Frame
Up to 3 months post-injury
Title
Number of Participants With Adherence With Vitamin D Supplementation
Description
Will measure adherence with vitamin D supplementation based on participants self report at the 6 week and 3 month visits.
Time Frame
Up to 3 months post-injury
Title
Number of Participants With Adverse Events (AE)
Description
A count of the participants who experienced adverse events will measure participant safety
Time Frame
Up to 12 months post-injury
Title
Serum Levels of Calcium
Description
Will measure participant safety
Time Frame
Up to 3 months post-injury
Title
Serum Levels of Parathyroid Hormone
Description
Helps the body to maintain stable levels of calcium in the blood
Time Frame
Up to 3 months post-injury
Title
Count of Participants Who Completed Blood Measures
Description
Will measure participants adherence to the blood measures of the protocol.
Time Frame
Up to 3 months post-injury
Title
Count of Participants Who Completed Radiographic Imaging Measures
Description
Count of participants who completed radiographic imaging measures to determine participant protocol adherence and assists with identifying healing status
Time Frame
up to 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult men or women ages 18-50 years Closed or low grade open (Gustilo type I or II) tibial or femoral shaft fracture Fracture treated with a reamed, locked, intramedullary nail Acute fracture (enrolled within 7 days of injury) Provision of informed consent. Exclusion Criteria: Osteoporosis Stress fractures Elevated serum calcium (>10.5 mg/dL) Atypical femur fractures as defined by American Society for Bone and Mineral Research (ASBMR) criteria Pathological fractures secondary to neoplasm or other bone lesion Patients with known or likely undiagnosed disorders of bone metabolism such as Paget's disease, osteomalacia, osteopetrosis, osteogenesis imperfecta etc. Patients with hyperhomocysteinemia Patients with an allergy to vitamin D or another contraindication to being prescribed vitamin D Patients currently taking an over the counter multivitamin that contains vitamin D and are unable or unwilling to discontinue its use for this study Patients who will likely have problems, in the judgment of the investigators, with maintaining follow-up Pregnancy Patients who are incarcerated Patients who are not expected to survive their injuries Other lower extremity injuries that prevent bilateral full weight-bearing by 6 weeks post-fracture.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gerard Slobogean, MD
Organizational Affiliation
University of Maryland
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Sheila Sprague, PhD
Organizational Affiliation
McMaster University
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Maryland, R Adams Cowley Shock Trauma Center
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21201
Country
United States
Facility Name
McMaster University, Center for Evidence-Based Orthopaedics
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8L 8E7
Country
Canada

12. IPD Sharing Statement

Citations:
PubMed Identifier
26429406
Citation
Sprague S, Petrisor B, Scott T, Devji T, Phillips M, Spurr H, Bhandari M, Slobogean GP. What Is the Role of Vitamin D Supplementation in Acute Fracture Patients? A Systematic Review and Meta-Analysis of the Prevalence of Hypovitaminosis D and Supplementation Efficacy. J Orthop Trauma. 2016 Feb;30(2):53-63. doi: 10.1097/BOT.0000000000000455.
Results Reference
background
PubMed Identifier
9006763
Citation
Omeroglu S, Erdogan D, Omeroglu H. Effects of single high-dose vitamin D3 on fracture healing. An ultrastructural study in healthy guinea pigs. Arch Orthop Trauma Surg. 1997;116(1-2):37-40.
Results Reference
background
PubMed Identifier
9528922
Citation
Jingushi S, Iwaki A, Higuchi O, Azuma Y, Ohta T, Shida JI, Izumi T, Ikenoue T, Sugioka Y, Iwamoto Y. Serum 1alpha,25-dihydroxyvitamin D3 accumulates into the fracture callus during rat femoral fracture healing. Endocrinology. 1998 Apr;139(4):1467-73. doi: 10.1210/endo.139.4.5883.
Results Reference
background
PubMed Identifier
3023034
Citation
Lidor C, Dekel S, Edelstein S. The metabolism of vitamin D3 during fracture healing in chicks. Endocrinology. 1987 Jan;120(1):389-93. doi: 10.1210/endo-120-1-389.
Results Reference
background
PubMed Identifier
3029136
Citation
Lidor C, Dekel S, Hallel T, Edelstein S. Levels of active metabolites of vitamin D3 in the callus of fracture repair in chicks. J Bone Joint Surg Br. 1987 Jan;69(1):132-6. doi: 10.1302/0301-620X.69B1.3029136.
Results Reference
background
PubMed Identifier
9177802
Citation
Omeroglu H, Ates Y, Akkus O, Korkusuz F, Bicimoglu A, Akkas N. Biomechanical analysis of the effects of single high-dose vitamin D3 on fracture healing in a healthy rabbit model. Arch Orthop Trauma Surg. 1997;116(5):271-4. doi: 10.1007/BF00390051.
Results Reference
background
PubMed Identifier
19047701
Citation
Study to Prospectively Evaluate Reamed Intramedullary Nails in Patients with Tibial Fractures Investigators; Bhandari M, Guyatt G, Tornetta P 3rd, Schemitsch EH, Swiontkowski M, Sanders D, Walter SD. Randomized trial of reamed and unreamed intramedullary nailing of tibial shaft fractures. J Bone Joint Surg Am. 2008 Dec;90(12):2567-78. doi: 10.2106/JBJS.G.01694.
Results Reference
background
PubMed Identifier
22258982
Citation
Duan X, Al-Qwbani M, Zeng Y, Zhang W, Xiang Z. Intramedullary nailing for tibial shaft fractures in adults. Cochrane Database Syst Rev. 2012 Jan 18;1:CD008241. doi: 10.1002/14651858.CD008241.pub2.
Results Reference
background
PubMed Identifier
10630795
Citation
Bhandari M, Guyatt GH, Tong D, Adili A, Shaughnessy SG. Reamed versus nonreamed intramedullary nailing of lower extremity long bone fractures: a systematic overview and meta-analysis. J Orthop Trauma. 2000 Jan;14(1):2-9. doi: 10.1097/00005131-200001000-00002.
Results Reference
background
PubMed Identifier
23035626
Citation
Bonafede M, Espindle D, Bower AG. The direct and indirect costs of long bone fractures in a working age US population. J Med Econ. 2013;16(1):169-78. doi: 10.3111/13696998.2012.737391. Epub 2012 Oct 22.
Results Reference
background
PubMed Identifier
23351958
Citation
Antonova E, Le TK, Burge R, Mershon J. Tibia shaft fractures: costly burden of nonunions. BMC Musculoskelet Disord. 2013 Jan 26;14:42. doi: 10.1186/1471-2474-14-42.
Results Reference
background
PubMed Identifier
17920421
Citation
Kanakaris NK, Giannoudis PV. The health economics of the treatment of long-bone non-unions. Injury. 2007 May;38 Suppl 2:S77-84. doi: 10.1016/s0020-1383(07)80012-x. Erratum In: Injury. 2007 Oct;38(10):1224.
Results Reference
background
PubMed Identifier
20182228
Citation
Bhandari M, Schemitsch EH. Stimulation of fracture healing: osteobiologics, bone stimulators, and beyond. J Orthop Trauma. 2010 Mar;24 Suppl 1:S1. doi: 10.1097/BOT.0b013e3181d2d683. No abstract available.
Results Reference
background
PubMed Identifier
20182234
Citation
Marsell R, Einhorn TA. Emerging bone healing therapies. J Orthop Trauma. 2010 Mar;24 Suppl 1:S4-8. doi: 10.1097/BOT.0b013e3181ca3fab.
Results Reference
background
PubMed Identifier
25879121
Citation
Schoelles K, Snyder D, Kaczmarek J, Kuserk E, Erinoff E, Turkelson C, Coates V. The Role of Bone Growth Stimulating Devices and Orthobiologics in Healing Nonunion Fractures [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2005 Sep 21. Available from http://www.ncbi.nlm.nih.gov/books/NBK285118/
Results Reference
background
PubMed Identifier
16362144
Citation
Veitch SW, Findlay SC, Hamer AJ, Blumsohn A, Eastell R, Ingle BM. Changes in bone mass and bone turnover following tibial shaft fracture. Osteoporos Int. 2006;17(3):364-72. doi: 10.1007/s00198-005-2025-y. Epub 2005 Dec 15.
Results Reference
background
PubMed Identifier
31446441
Citation
Hojsager FD, Rand MS, Pedersen SB, Nissen N, Jorgensen NR. Fracture-induced changes in biomarkers CTX, PINP, OC, and BAP-a systematic review. Osteoporos Int. 2019 Dec;30(12):2381-2389. doi: 10.1007/s00198-019-05132-1. Epub 2019 Aug 24.
Results Reference
background
PubMed Identifier
31768262
Citation
Sprague S, Bzovsky S, Connelly D, Thabane L, Adachi JD, Slobogean GP; Vita-Shock Investigators. Study protocol: design and rationale for an exploratory phase II randomized controlled trial to determine optimal vitamin D3 supplementation strategies for acute fracture healing. Pilot Feasibility Stud. 2019 Nov 22;5:135. doi: 10.1186/s40814-019-0524-4. eCollection 2019.
Results Reference
derived

Learn more about this trial

Optimal Vitamin D3 Supplementation Strategies for Acute Fracture Healing

We'll reach out to this number within 24 hrs